Print

HVTN 039

A phase I trial to evaluate the safety, tolerability and immunogenicity of high dose live recombinant canarypox ALVAC-HIV vaccine, (vCP1452) in HIV-1 uninfected adult participants

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID), HIV Vaccine Trials Network (HVTN) December 03, 2001
ALVAC vCP1452 Canarypox gp120, TM gp41, gag, protease, nef, pol MN/LAI
ALVAC vCP1452 Viral Vector - Pox
USA 110
NCT00027261
https://www.clinicaltrials.gov/ct2/show/NCT00027261